Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS, Merck develop muraglitazar for diabetes: terminated

Executive Summary

Bristol-Myers Squibb and Merck & Co. will jointly develop and commercialize Bristol's muraglitazar, a dual peroxisome proliferator-activated receptor (PPAR) agonist that is in Phase III clinical trials to manage Type II diabetes and the lipid abnormalities often associated with the disease, especially high triglyceride and low HDL levels.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register